Bulletin
Investor Alert

New York Markets Close in:

Topics

Biotechnology

Video

Can Wearables Detect Covid-19 Symptoms? I Wore Six to Find Out

  • Can Wearables Detect Covid-19 Symptoms? I Wore Six to Find Out Can Wearables Detect Covid-19 Symptoms? I Wore Six to Find Out 6:25
    On the Front Line of Developing a Covid-19 Vaccine On the Front Line of Developing a Covid-19 Vaccine 28:59
    How AI helps doctors diagnose diseases more accurately How AI helps doctors diagnose diseases more accurately 2:13
    Coronavirus Outbreak Tests New Vaccine Development Strategy Coronavirus Outbreak Tests New Vaccine Development Strategy 4:18
11:03 a.m. Today - By Jaimy Lee
An experimental antibody treatment reduced viral load in some COVID-19 patients. That may also be a positive sign for vaccines ‘If treatment works, prophylaxis should work, and if prophylaxis works, vaccines should work,’ Raymond James analysts told investorsPromising new clinical data for an experimental COVID-19 treatment hints at a secondary but possibly more important takeaway for investors: if this neutralizing antibody treatment works, so will the coronavirus vaccines that are in development.
8:21 a.m. Today - By Lina Saigol
FDA broadens U.S. safety inquiry into AstraZeneca COVID-19 vaccine, report says, raising prospect of further delays Clinical trials in the U.K., Brazil, India and South Africa resumed after the drugmaker paused them following a volunteer's “unexplained illness.”
7:59 a.m. Today - By Mike Murphy
Moderna CEO tells FT that coronavirus vaccine won't be ready by Election DayModerna Inc.'s potential coronavirus vaccine will not be ready by the U.S. presidential election, the drug maker's chief executive told the Financial Times on Wednesday.
7:57 a.m. Today - Barrons.com
Biotech Pulmonx Shares Climb in Trading Debut The company raised $190 million after pricing its deal above its expected range.
7:36 a.m. Today - By Ciara Linnane
Pulmonx shares soar 118% in trading debutShares of Pulmonx, a maker of treatments for lung diseases including emphysema, rose 118% in their trading debut Thursday, after the company's initial public offering priced above range. The deal priced at $19 a share, above its proposed price range of $17 to $18. The company upsized the deal on Wednesday and raised the proposed price range. Pulmonx sold 10 million shares to raise $190 million. Shares are trading on Nasdaq under the ticker "LUNG." BofA, and Morgan Stanley were lead underwriters on the deal, with Stifel, Wells Fargo and Canaccord acting as co-managers. Proceeds of the deal will be used to hire sales and marketing people, fund R&D, to pay a success fee to Oxford of $1.9 million and for working capital. "We are a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD)," the company says in its prospectus.
3:36 a.m. Today - By Philip van Doorn
Here are the biggest winners in a solid third quarter for U.S. stocks Gains were spread across tech, materials, industrials and retailersGains were spread across tech, materials, industrials and retailers.
12:25 p.m. Sept. 30, 2020 - By MarketWatch Automation
1:11 a.m. Sept. 30, 2020 - By Steve Goldstein
Moderna climbs after saying COVID-19 vaccine generates antibodies in older adultsModerna rose 4% in early premarket trade as it said late Tuesday that early-stage data suggests its COVID-19 vaccine can generate neutralizing antibodies in older and elderly adults at levels comparable to those in younger adults. The study was published in . Moderna's stock has surged 251% this year.
2:08 p.m. Sept. 29, 2020 - Barrons.com
Regeneron Says Antibodies Helped Covid Patients Recover Faster Time is of the essence for antibody treatments because if a successful vaccine comes soon, that would curtail the need for antibody infusions.
12:25 p.m. Sept. 29, 2020 - By MarketWatch Automation
12:52 p.m. Sept. 28, 2020 - By MarketWatch Automation
4:56 a.m. Sept. 28, 2020 - Barrons.com
The Pandemic Speeds Up the Health-Care Revolution The drive to quickly conquer Covid-19 has accelerated innovation. Barron’s Roundtable experts highlight the most promising developments and best investment bets.
3:34 a.m. Sept. 28, 2020 - By Jaimy Lee
Inovio's shares tumble 33% as COVID-19 vaccine trial is put on holdShares of Inovio Pharmaceuticals Inc. were halted and then fell 33.6% when they resumed premarket trading on Monday when the company said the Phase 2/3 clinical trial for its COVID-19 vaccine candidate was in a "partial clinical hold" while it answered additional questions from the Food and Drug Administration. The hold is not due to an adverse event, which is what paused the Phase 3 study for AstraZeneca and the University of Oxford's experimental coronavirus vaccine. Inovio said in a news release that it is working on answering the regulator's questions, it plans to respond to the FDA in October, and then the agency has 30 days to issue its decision about whether the trial can move forward. The Phase 1 trial is still underway. Inovio's stock has soared 413.3% so far this year, while the S&P 500 is up 21.%.
3:27 a.m. Sept. 28, 2020 - By Jaimy Lee
There are four coronavirus vaccines in late-stage studies — here’s how they differ The vaccine candidates vary on everything from refrigeration needs to effectiveness goals and number of dosesJohnson & Johnson’s investigational COVID-19 vaccine entered Phase 3 clinical trials this week, making it the fourth vaccine candidate in the U.S. to do so and providing additional details that can help investors differentiate the pool of late-stage coronavirus vaccines.
3:25 a.m. Sept. 28, 2020 - By Ciara Linnane
Biotech Oncorus to offer 5.8 million shares in planned IPO, priced at $14 to $16 eachBiotech Oncorus Inc. set terms for its initial public offering on Monday with plans to offer 5.8 million shares priced at $14 to $16 each. The company has applied to list on Nasdaq, under the ticker "ONKR." Jefferies, Evercore ISI and Piper Sandler are underwriting the deal with proceeds earmarked for clinical trials, to expand manufacturing capabilities and for working capital. "We are a clinical stage biopharmaceutical company focused on developing next-generation viral immunotherapies to transform outcomes for cancer patients," the company says
11:54 a.m. Sept. 25, 2020 - By Andrea Riquier
Forget 2020. Here's how to invest for the next decadeYes, 2020 brought a lot of surprises. But here are some solid bets for your portfolio for the next several years.
11:16 a.m. Sept. 25, 2020 - MarketWatch.com
Everything you need to know about what it would take for the FDA to approve a COVID-19 vaccineYou’ve probably been wondering how the Food and Drug Administration will decide if a COVID-19 vaccine is safe and effective.
10:31 a.m. Sept. 25, 2020 - Barrons.com
PMV Pharma Soars 115% as Biotech IPOs Take Off Three biotech stocks all achieved double-digit gains in the first day of trading on Friday.
8:37 a.m. Sept. 25, 2020 - By Tomi Kilgore
PMV Pharmaceutical's stock nearly doubles in its debutPMV Pharmaceuticals Inc.'s stock debuted with a bang Friday, as the the stock opened at nearly double the initial public offering price. The first trade was at $35.00 at 12:09 p.m. Eastern for 346,817 shares, or 94.4% above . The raised $211.8 million in the IPO, and was valued at $774 million at the IPO price. The stock has mostly held its gains since the open, to be trading 93.6% above its IPO price The company went public at a time that the Renaissance IPO ETF has rallied 23.3% over the past three months, while the S&P 500 has gained 5.8%.
4:47 a.m. Sept. 25, 2020 - Barrons.com
Four Biotech IPOs Are on Tap for Friday PMV Pharmaceuticals, Prelude Therapeutics, Graybug Vision and Orphazyme will make their market debuts.
3:30 a.m. Sept. 25, 2020 - By Jaimy Lee
Novavax stock rises as it announces vaccine manufacturing deal with EndoShares of Novavax Inc. jumped 6.8% in premarket trading on Friday after the company announced a COVID-19 vaccine manufacturing deal with Endo International . Endo's stock is up 7.3%. One of Endo's subsidiaries will provide fill-finish manufacturing services at a factory in Rochester, Mich.; the product being produced is expected to be used in the company's Phase 3 trials for NVX-CoV2373 in the U.S. as well as for potential general distribution to the public if the vaccine candidate receives any type of regulatory approval or authorization. Novavax CEO Stanley Erck said in the news release that the company is preparing for its pivotal Phase 3 clinical trial in the U.S. "to get underway very soon." On Thursday Novavax had announced that its vaccine candidate had entered Phase 3 clinical trials in the U.K. So far this year Novavax's stock is up 2,473.9%, shares of Endo are down 35.6%, and the S&P 500 is up 0.5%.
2:16 a.m. Sept. 25, 2020 - By Tomi Kilgore
PMV Pharmaceuticals prices IPO at top end of expectations, raises $211.8 millionPMV Pharmaceuticals Inc.'s initial public offering priced at $18 a share, which was at the top of the expected range of $16 to $18 a share. The said late Thursday that it sold 11.765 million shares in the IPO, which was , to raise $211.8 million. With 43 million shares outstanding after the IPO, the pricing valued that company at $773.99 million. Goldman Sachs, BofA Securities, Cowen and Evercore are the joint book-running managers. The stock is expected to begin trading Friday on the Nasdaq under the ticker symbol "PMVP." The company is going public at a time that the Renaissance IPO ETF has rallied 20.1% over the past three months, while the S&P 500 has gained 5.3%.
9:45 a.m. Sept. 24, 2020 - By Tomi Kilgore
PMV Pharma upsizes IPO by 60%, to now raise up to $211.8 millionPMV Pharmaceuticals Inc. has upsized its initial public offering by 60%, as the oncology company now looks to raise up to $211.8 million. The company is now offering 11.765 million shares in the IPO, , while the IPO's expected pricing range remains at between $16 and $18 a share. If the underwriters of the offering exercise options to buy up to an additional 1.76 million shares to cover overallotments, the company could raise up to $243.5 million. The company is looking to go public at a time that the Renaissance IPO ETF has rallied 60.7% year to date, while the S&P 500 has gained 1.4%.
9:34 a.m. Sept. 24, 2020 - By Tomi Kilgore
Immunome sets IPO terms, to raise up to $32.5 millionImmunome Inc. set terms for its initial public offering, in which the Pennsylvania-based biopharmaceutical company focused on oncology looks to raise up to $32.5 million. The company is offering 2.5 million shares in the IPO, which is expected to price between $11 and $13 a share. With 9.3 million shares outstanding after the IPO, the pricing values the company at up to $120.7 million. The stock is expected to list on the Nasdaq under the ticker symbol "IMNM." The book-running managers are Ladenburg Thalmann and Chardan. For the six months ended June 30, the company recorded a net loss of $5.4 million on no revenue, after a loss of $4.8 million on no revenue in the same period a year ago. The company is looking to go public at a time that the Renaissance IPO ETF IPO has rallied 23.2% over the past three months, while the iShares Nasdaq Biotechnology ETF has declined 3.7% and the S&P 500 has gained 7.5%.
6:52 a.m. Sept. 24, 2020 - Barrons.com
Taysha Gene Therapies Climbs in Trading Debut The biotech is one of several pharmaceutical and biotech companies going public this week.
6:52 a.m. Sept. 24, 2020 - MarketWatch.com
U.K. COVID-19 trial set to deliberately infect people with virus to speed up vaccine developmentThe U.K. government is considering launching ‘human challenge trials’ where healthy volunteers are purposefully infected with the new coronavirus in a bid to speed up development of a vaccine.
1:28 p.m. Sept. 23, 2020 - By Wallace Witkowski
7:06 a.m. Sept. 23, 2020 - By Jaimy Lee
FDA commissioner: It's up to drug makers developing vaccines to seek approval or EUADrug makers developing COVID-19 vaccines will decide to seek full approval from the Food and Drug Administration or the less rigorous emergency use authorization (EUA), according to remarks made by FDA commissioner Dr. Stephen Hahn during a congressional hearing on Wednesday. "This will be based upon the trial meeting pre-specified success criteria that were established by that sponsor," Hahn said. The EUA option was put into place during the pandemic to speed up the arrival of new tests, treatments, and vaccines; however, once the U.S. ends the public health emergency, the EUA is no longer valid. Four COVID-19 vaccine candidates are currently in Phase 3 clinical trials, including candidates developed by AstraZeneca's and the University of Oxford, BioNTech and Pfizer Inc. , Johnson & Johnson , and Moderna Inc. .
6:52 a.m. Sept. 23, 2020 - By Jaimy Lee
Fauci predicts U.S. will know if COVID-19 vaccines are effective by "November or December"Dr. Anthony Fauci, director of National Institute of Allergy and Infectious Diseases, expects to see data from the Phase 3 clinical trials of some COVID-19 vaccine candidates indicating whether the vaccines are safe and effective by "November or December" of this year. Fauci made the remarks while testifying during a congressional hearing on Wednesday. There are four experimental coronavirus vaccines in late-stage studies in the U.S., including candidates developed by AstraZeneca's and the University of Oxford, BioNTech and Pfizer Inc. , Johnson & Johnson , and Moderna Inc. . "We feel strongly that if we have a combination of adherence to the public health measures together with a vaccine that will be distributed to people in this country and worldwide, we may be able to turn around this terrible pandemic that which we have been experiencing," he said. Drs. Robert Redfield, director for the Centers for Disease Control and Prevention, and Stephen Hahn, commissioner of the Food and Drug Administration, are also testifying.
4:40 a.m. Sept. 22, 2020 - By Jaimy Lee
Vaccinex's stock falls after investigational drug fails Huntington's disease studyShares of Vaccinex Inc. tumbled 61.6% in premarket trading on Tuesday after the preclinical biotechnology company said an experimental Huntington's disease treatment, pepinemab, did not meet the primary endpoints in a Phase 2 double-blind, placebo-controlled clinical trial. Earlier this month, Vaccinex had announced plans to study pepinemab in combination with Merck & Co. Inc.'s Keytruda as a possible treatment for advanced forms of metastatic head and neck squamous cell carcinoma. Vaccinex's stock is up 12.8% so far this year. The S&P 500 has gained 1.5%.
10:31 a.m. Sept. 21, 2020 - By Tomi Kilgore
Graybug Vision looks to raise up to $80 million as IPO terms setGraybug Vision Inc. set terms of its initial public offering, in which the California-based biopharmaceutical company focused on retina and optic never disease treatments looks to raise $79.7 million. The company is offering 4.79 million shares in the IPO, which is expected to price between $15 and $17 a share. With 19.16 million shares outstanding after the IPO, the expected pricing would value the company at up to $325.6 million. The stock is expected to list on the Nasdaq under the ticker symbol "GRAY." SVB Leerink and Piper Sandler are the lead underwrites. For the six months ended June 30, the company recorded a net loss of $18.5 million on no revenue, after a loss of $19.1 million on no revenue in the same period a year ago. The company is looking to go public at a time that the Renaissance IPO ETF has gained 21.0% over the past three months while the S&P 500 has edged up 4.7%.
3:30 a.m. Sept. 21, 2020 - By Jaimy Lee
Initial data from a pair of clinical trials may revive interest in arthritis drugs as COVID-19 treatments Lilly and Roche both say they both expect to publish this week’s clinical-trial findings in peer-reviewed medical journalsThere is some renewed hope for rheumatoid arthritis drugs like Eli Lilly’s Olumiant and Roche’s Actemra as possible COVID-19 treatments after a series of clinical setbacks this summer seemed to close the door on the category’s potential.
3:07 a.m. Sept. 21, 2020 - By Tomi Kilgore
Illumina's stock falls after $8 billion deal to buy Grail confirmedShares of Illumina Inc. dropped 5.3% in premarket trading Monday, after the gene sequencing company confirmed a deal to buy Grail Inc. for $8 billion in cash and stock. that an announcement of the deal, in which Illumina pays $7.1 billion for the part of Grail it doesn't already own, would be announced Monday. The report said the deal for the developer of a blood test that helps detect cancer, is expected to be announced Monday. Illumina said the deal includes $3.5 billion in cash and $4.5 billion in Illumina shares. "GRAIL extends Illumina's portfolio to include cancer screening, diagnosis and cancer monitoring, creating a portfolio of best-in-class, proprietary tests in each of the major oncology testing application areas," Illumina said in a statement. The stock has dropped 10.9% year to date through Friday, while the iShares Nasdaq Biotechnology ETF has rallied 13.1% and the S&P 500 has gained 2.8%.
3:00 a.m. Sept. 19, 2020 - Barrons.com
A Biotech Pro Bought Up These 3 Stocks Perceptive Advisors and its hedge fund recently invested a total of $60 million in Athenex, Albireo, and Quotient stock. Two of the stocks are slumping in 2020.
9:16 a.m. Sept. 18, 2020 - By Lina Saigol
How this Nasdaq-U.K.-listed Chinese biotech is revolutionizing cancer treatment Biotech company Chi-Med could list in Hong Kong as soon as 2021Chi-Med has been granted three U.S. Food and Drug Administration Fast Track Designations for its cancer drugs.
8:07 a.m. Sept. 18, 2020 - By Levi Sumagaysay
How long will the Silicon Valley employees who can't work from home keep getting paid?Cafeteria workers, janitors, security guards and shuttle drivers have mostly avoided layoffs as tech firms continue to push back their return to campuses, but that is starting to change
8:04 a.m. Sept. 18, 2020 - By Tomi Kilgore
Athira Pharma's stock jumps at its open, with the first trade 17% above the IPO priceShares of Athira Pharma Inc. rallied in their public debut, as the first trade was 17.4% above the initial public offering price. The Seattle-based biopharmaceutical company's upsized IPO priced late Thursday at $17 share, at the top of the expected range of $15 to $17 a share. The stock's first trade on the Nasdaq was at $19.95 at 12.01 p.m. Eastern for 7,69,298 shares. The company sold 12 million shares in the IPO, up from previous expectations of 10 million shares, to raise $204 million. The company was valued at about $489.8 million at the IPO price. The stock has pulled back since it opened, to trade up just 1.6%. Athira's public debut comes at the end of , which was highlighted by Snowflake Inc.'s red-hot debut earlier this week. The Renaissance IPO ETF has rallied 20.1% over the past three months, while the S&P 500 has gained 7.3%.
2:27 a.m. Sept. 18, 2020 - By Ciara Linnane
Athira Pharma prices upsized IPO at $17, high end of price rangeAthira Pharma Inc. priced its initial public offering at $17 a share, the top end of its proposed price range. The company upsized the deal to 12 million shares from an original plan to offer 10 million shares, to raise $204 million. The stock will start trading on Nasdaq later Friday, under the ticker "ATHA." Goldman Sachs, Jefferies and Stifel were lead book runners on the deal with JMP Securities acting as co-manager. Proceeds will be used to finance clinical trials. "We are a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration," the company says in its IPO prospectus.
12:55 a.m. Sept. 18, 2020 - Barrons.com
How This Nasdaq-U.K.-Listed Chinese Biotech Is Revolutionizing Cancer Treatment Chi-Med has been granted three U.S. Food and Drug Administration Fast Track Designations for its cancer drugs.
9:16 a.m. Sept. 17, 2020 - By Andrea Riquier
ETF Wrap: How to think about - and play - the wave of M&A activityETF Wrap is a briefing of what investors need to know in the exchange-traded sector, including exclusive commentary and interviews on the industry from MarketWatch
Browse topics:

Filter results by

Location

Us (764)

Europe (233)

Asia Pacific (232)

China (214)

Eu (185)

Japan (158)

Issue

General (432)

Opinion (243)

Markets/exchanges (207)

Market News (204)

Commodities (197)

Economy (168)

Link to MarketWatch's Slice.